MPLN vs. AMWL, AUGX, PHR, RVNC, NVRO, AVXL, NAUT, FBLG, TRML, and ACIU
Should you be buying MultiPlan stock or one of its competitors? The main competitors of MultiPlan include American Well (AMWL), Augmedix (AUGX), Phreesia (PHR), Revance Therapeutics (RVNC), Nevro (NVRO), Anavex Life Sciences (AVXL), Nautilus Biotechnology (NAUT), FibroBiologics (FBLG), Tourmaline Bio (TRML), and AC Immune (ACIU). These companies are all part of the "medical" sector.
American Well (NYSE:AMWL) and MultiPlan (NYSE:MPLN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
MultiPlan has a net margin of -65.83% compared to MultiPlan's net margin of -137.32%. American Well's return on equity of -8.11% beat MultiPlan's return on equity.
MultiPlan has higher revenue and earnings than American Well. MultiPlan is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
American Well received 22 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 47.76% of users gave American Well an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.
American Well has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, MultiPlan has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
In the previous week, American Well and American Well both had 2 articles in the media. American Well's average media sentiment score of -0.03 beat MultiPlan's score of -0.05 indicating that MultiPlan is being referred to more favorably in the news media.
56.0% of American Well shares are owned by institutional investors. Comparatively, 87.2% of MultiPlan shares are owned by institutional investors. 12.9% of American Well shares are owned by insiders. Comparatively, 8.2% of MultiPlan shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
American Well presently has a consensus price target of $1.00, indicating a potential upside of 104.75%. MultiPlan has a consensus price target of $2.00, indicating a potential upside of 234.78%. Given American Well's higher possible upside, analysts plainly believe MultiPlan is more favorable than American Well.
Summary
MultiPlan beats American Well on 9 of the 15 factors compared between the two stocks.
Get MultiPlan News Delivered to You Automatically
Sign up to receive the latest news and ratings for MPLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MPLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MultiPlan Competitors List
Related Companies and Tools
